Bristol-Myers Squibb stock (US1078421011): $600M Hengrui deal eyes $15.2B pipeline boost

Bristol-Myers Squibb has entered a landmark collaboration with Shanghai-based Hengrui Pharma, gaining exclusive worldwide rights (ex-China) to 13 early-stage programs across oncology, hematology, and immunology. The deal includes a $600 million upfront payment, $175 million in 2027, a potential $175 million in 2028, and up to $14.25 billion in milestones plus royalties, according to BioXconomy as of May 2026. Expected to close in Q3 2026 pending antitrust approval.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb focuses on discovering, developing, and delivering innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience. The company operates a global biopharma model, with significant R&D investment supporting a pipeline of blockbuster drugs like Opdivo and Eliquis. US investors track BMY for its leadership in immuno-oncology and exposure to the world's largest pharma market.

Main revenue and product drivers for Bristol-Myers Squibb

Key products include Opdivo (nivolumab) for cancer immunotherapy, generating billions in annual sales, and Eliquis (apixaban) for anticoagulation. The portfolio spans multiple therapeutic areas, with oncology contributing over 40% of revenue in recent periods. This Hengrui deal bolsters the pipeline with 13 assets, including four oncology/hematology programs transferred directly and five joint discovery efforts, per BioXconomy as of May 2026.

Industry trends and competitive position

The biopharma sector faces patent cliffs but benefits from advances in ADCs and bispecifics, areas where Bristol-Myers Squibb competes with peers like Merck and Roche. This deal taps China's innovative pipeline, enhancing BMS's position amid rising demand for next-gen therapies in the US market.

Why Bristol-Myers Squibb matters for US investors

Listed on NYSE, Bristol-Myers Squibb offers US investors direct exposure to a diversified pharma giant with heavy reliance on the US healthcare system. The Hengrui partnership signals strategic expansion into high-potential Asian innovation, potentially fueling long-term growth amid domestic reimbursement dynamics.

Conclusion

The Hengrui collaboration positions Bristol-Myers Squibb to refresh its pipeline with 13 promising programs, backed by substantial near-term payments and milestone potential. While awaiting Q3 2026 closure, this move underscores BMS's focus on external innovation. Investors monitor execution amid competitive oncology pressures.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.